ACRS - NASDAQ
Aclaris Therapeutics, Inc.
$4.61
-0.54%Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
At a Glance
Live Snapshotacrs
Operating Expenses
Last Annual Value
82.11M
3-Year CAGR
-9%
5-Year CAGR
9%
10-Year CAGR
15%
Aclaris Therapeutics, Inc. Competitors Analysis of Operating Expenses
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Aclaris Therapeutics, Inc. NASDAQ:ACRS | 82.11M | -9.4% | -2.2% | 5.4% | |
 908 Devices Inc. NASDAQ:MASS | 67.84M | -0.1% | 8.4% | N/A | |
 Senseonics Holdings, Inc. NASDAQ:SENS | 84.10M | 2.2% | 8.3% | 7.2% | |
 Atlantic International Corp. NASDAQ:ATLN | 96.22M | 24.1% | 1.3% | 48.8% | |
 Health Catalyst, Inc. NASDAQ:HCAT | 140.24M | -18.5% | -11.7% | N/A | |
 Invivyd, Inc. NASDAQ:IVVD | 105.24M | -20.9% | -14.2% | N/A | |
 Orchestra BioMed Holdings, Inc. NASDAQ:OBIO | 85.10M | 16.3% | 32.5% | N/A | |
 Pyxis Oncology, Inc. NASDAQ:PYXS | 95.89M | 5.3% | 6.6% | N/A | |
 Neuronetics, Inc. NASDAQ:STIM | 103.74M | 8.0% | 7.8% | 10.9% | |
 Vor Biopharma Inc. NASDAQ:VOR | 371.64M | 44.7% | 40.0% | N/A | |
 Cabaletta Bio, Inc. NASDAQ:CABA | 170.59M | 32.6% | 30.2% | N/A |
Aclaris Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your ACRS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.